Multidrug-resistant Candida auris has emerged as a cause of insidious hospital outbreaks and complicated infections. We present the analysis of an ongoing C. auris outbreak including the largest published series of C. auris bloodstream infection. All C. auris-positive patients from April-2016 to January-2017 were included.
| INTRODUC TI ON
Recently, the newly described yeast species Candida auris has emerged as resistant fungal pathogen responsible for hospital outbreaks, in hospitals and especially in intensive care units (ICU), in Asia, the Middle East, Africa, Latin-America, North-America and Europe. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] C. auris has the capacity to survive in the environment for up to 2 weeks despite usual cleaning measures. This feature could be due to the use of cationic surface-active products like quaternary ammonium, disinfectants that until very recently its efficacy against this species was unknown. Currently, the activity of sporicidal disinfectants and hydrogen peroxide-based disinfectants against C. auris has been demonstrated. 12, 13 Likewise, many colonised biomedical devices could be also implicated in cross-infection, maintenance of reservoirs and therefore persistence of an outbreak. [14] [15] [16] [17] Furthermore, C. auris is not identified or misidentified by commonly used commercial systems such as API20C-AUX and Vitek 2, thus delaying the appropriate antifungal therapy and the suitable measures to prevent its spread. [18] [19] [20] Proteomic and molecular methods are needed in order to identify and differentiate C. auris from other Candida species, but these techniques are not available in many clinical laboratories, so the real burden of infections associated with C. auris could be underestimated.
Candida auris infection is characterised by a difficult antifungal management. Although there are no established breakpoints for

C. auris, studies have demonstrated elevated resistance to azoles
with minimum inhibitory concentration (MIC) 256 μg/mL and ≥2 μg/ mL to fluconazole and voriconazole, respectively, and variable susceptibility to other azoles, amphotericin B and echinocandins. 4, 6, 21, 22 Finally, delay in species identification, presence of comorbidity and clinical severity of infected patients (critical care patients) and antifungal resistance lead to high mortality rates and presence of frequent complications (septic metastasis and recurrent/persistent candidaemia). 13, 23 Therefore, C. auris infections are a worrisome healthcare problem and a daily challenge for the clinician dealing with infected or colonised patients.
The aim of this report is to describe the first 10 months of our ongoing C. auris outbreak including a remarkable number of candidaemia. We hope that by sharing our experience, we could help expanding the knowledge about this new and threatening microorganism. 
| ME THODS
| Outbreak setting
| Inclusion criteria and clinical demographic data
Only patients with C. auris colonisation or infection were included.
Demographic characteristics, comorbidity, duration and allocation during present and previous recent hospitalisations, clinical presentation, source of infection, exposure to antimicrobials and clinical outcomes of patients with C. auris infection were collected retrospectively.
| Definitions
Candida auris colonisation was defined as a positive culture from 
| Sample collection from environment and healthcare workers
Environmental samples were collected from SICU, MICU and surgical theatres surfaces (walls, tables, medical equipment, keyboards, screens, taps, etc.) using sterile cotton gauze moistened with sterile normal saline (0.9%) before and after cleaning. Hands and ear canals of healthcare workers (HCW), present on different days, were also screened using sterile cotton swabs. Cotton gauzes and swabs were directly transported to the laboratory in a sterile tube, and placed in Sabouraud dextrose with chloramphenicol (Becton Dickinson, Franklin Lakes, NJ, USA) and incubated at 35°C for 72 hours.
| Laboratory methods
Samples from patients, HCW and environment were processed ac- Fragment Length Polymorphisms (AFLP) fingerprinting to distinguish C. auris from closely related species as described previously. 26 Candida haemulonii (CBS5149, CBS5150, CBS7801 and CBS7802), Candida pseudohaemulonii (CBS10004, KTC17807 and JCM12453) and Candida duobushaemulonii (CBS7798, CBS7799, CBS7800, CBS9754 and 10-08-05-27) were used as controls.
The analysis also included representative isolates of a number of global published outbreaks to identify a geographic origin of this outbreak: Spain (n = 58), Venezuela (n = 19), India (n = 12), UK (n = 14), South Africa (n = 4) and Oman (n = 4). 
| RE SULTS AND D ISCUSS I ON
| Outbreak extent and control
During 
| Candida auris infection episodes
During the 10-month studied period, 41 C. auris infections were detected, all of them candidaemia episodes. All candidaemia events were observed in adult patients (21- and previous surgery (85.4). Candida score was ≥3 only in 58.5%
patients at the onset of candidaemia. 28 In a study that included 27
ICUs in India, underlying respiratory illness, vascular surgery, prior antifungal exposure and low APACHE II score were identified as risk factors significantly associated with candidaemia by C. auris.
29
Comparing these findings with those previously reported, risk factors for candidaemia by C. auris are similar to those found in candidaemia by other Candida species. 30, 31 Apart from blood cultures, was administered in combination with an echinocandin. In our series, the crude mortality rate at 30 days was 41.4%, similar to that observed in other studies: 30%-60%, 1,2,32,33 but higher than the results (28%) reported by Calvo et al. 5 Because it is commonly observed that invasive Candida infections occur in critically ill patients with many comorbidities, attributable mortality rate for C. auris candidaemia is difficult to assess and it should be analysed in future studies.
During the candidaemia episode, 5 patients (12.2%) developed septic metastatic complication which included: spondylodiscitis (n = 2), ventriculitis in a patient with a ventriculoperitoneal drainage (n = 1) and endocarditis (n = 2). In all cases, these complications appeared despite adequate treatment of the candidemia episode based on in vitro susceptibility data (Tables 2 and 3 Guidance -Medscape -May 18, 2017), all isolates were susceptible to echinocandins. Anidulafungin MICs were higher than those of micafungin and caspofungin (geometric mean MIC 0.121 μg/mL, 0.057 μg/mL and 0.056 μg/mL, respectively). However, 7%-40%
TA B L E 2 Main clinical characteristics of patients with metastatic complications
| Microbiological findings
echinocandin-resistant C. auris isolates have been reported by other authors in small series of isolates. 32, 33 Our isolates were highly resistant to fluconazole (MICs >256 μg/mL). Voriconazole and posaconazole MICs were ≤2 μg/mL and ≤0.25 μg/mL for 82% and 100% of the isolates, respectively. Comparing these results with those reported in other large studies, it seems that C. auris has demonstrated global resistance to fluconazole and voriconazole. 1, 5, 19, 32, 33, 40 Although there is no evidence that isavuconazole is effective for the invasive candidiasis treatment, all our isolates were susceptible to isavuconazole (MICs ≤ 1 μg/mL) by Etest methodology. Amphotericin 
